Denosumab
Indication
Bone metastasis from solid tumours (NICE TA265)
MHRA Drug Safety Update - Denosumab: updated recommendations
Red
Brand:
Xgeva®
Nice TA:
265
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Endocrine system